Ever expanding rapid diagnostic products

Inverness Medical Innovations develops and manufactures rapid diagnostic products for use in preventive as well as interventional therapies.

Photo: Ever expanding rapid diagnostic products

Information from patients’ body fluids, or tissue, assists physicians to diagnose disease, as well as to measure a patient’s response to a specific therapy. Its range of clinical diagnostic products already includes, the well-known brands Clearview, Inverness Medical TestPack, Binax, Determine, BioStar, and many others. ‘Our high quality immunoassays in pregnancy testing and fertility, respiratory, enteric and infectious diseases, autoimmune disorders, osteoporosis, cancer and cardiology, have demonstrated proven efficiency in clinics, hospitals and laboratories internationally,’ the firm points out.

Currently, Inverness Medical Innovations reports that it is exploring opportunities to optimise the use of its technologies, as well as continually evaluating other technological advances, for development or acquisition, in a variety of medical/health areas.

14.11.2006

More on the subject:

Related articles

Photo

Article • Advances in mobile monitoring

Wearable technology transforms laboratory medicine

Remote monitoring via microfluidic platforms, AI-assisted sensor systems, and more: Attendees of the Labmed Forum at Medica saw impressive examples on how wearable technology is becoming a…

Photo

News • Staining instrument family

New pathology lab solutions debut at ECP 2025

Agilent Technologies Inc. announced the introduction of its Dako Omnis family of instruments with three new models—Agilent Dako Omnis 110, 165, and 165 Duo—designed to meet the evolving needs of…

Photo

News • Patient involvement enables research

Tumor vesicles as a promising biomarker for early cancer detection

Tumor vesicles may serve as early indicators of cancer and help monitor the effectiveness of treatments. Now, researchers discovered a new way to detect these vesicles.

Related products

Subscribe to Newsletter